Reported Saturday, MindMed Unveils Phase 2b Data Of MM120 For Generalized Anxiety Disorder At American Psychiatric Association Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
MindMed unveiled Phase 2b data of MM120 for Generalized Anxiety Disorder at the APA Annual Meeting, showing significant clinical benefits over placebo. The drug achieved a 65% clinical response rate and a 48% remission rate at 12 weeks. Additionally, MindMed presented two new studies on the burden of GAD in the US.
May 06, 2024 | 7:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MindMed's MM120 shows significant clinical benefits in Phase 2b trial for Generalized Anxiety Disorder, with high response and remission rates.
Positive Phase 2b trial results typically lead to increased investor confidence and can significantly impact a biotech company's stock price in the short term. The successful trial outcomes and the presentation at a major psychiatric meeting highlight the potential of MM120, likely attracting investor attention and potentially driving up MindMed's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100